IN2012CH05549A - - Google Patents

Download PDF

Info

Publication number
IN2012CH05549A
IN2012CH05549A IN5549CH2012A IN2012CH05549A IN 2012CH05549 A IN2012CH05549 A IN 2012CH05549A IN 5549CH2012 A IN5549CH2012 A IN 5549CH2012A IN 2012CH05549 A IN2012CH05549 A IN 2012CH05549A
Authority
IN
India
Prior art keywords
composition
ibuprofen
pharmaceutically acceptable
acceptable salt
active ingredient
Prior art date
Application number
Inventor
Prodduturi Dr Suneela
Chandra Illapakurthy Dr Ashok
Kumar Alluri Pavan
Kandarapu Dr Raghupathi
S Rudraraju Dr Varma
Original Assignee
Aizant Drug Res Solution Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aizant Drug Res Solution Private Ltd filed Critical Aizant Drug Res Solution Private Ltd
Priority to PCT/IB2013/061370 priority Critical patent/WO2014102745A1/en
Priority to IN5549CH2012 priority patent/IN2012CH05549A/en
Publication of IN2012CH05549A publication Critical patent/IN2012CH05549A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Abstract

The present invention relates to invention relates to a sustained release composition of ibuprofen or pharmaceutically acceptable salt thereof, comprising high drug load of active ingredient and its method of preparation. The sustained release pharmaceutical composition comprising ibuprofen or a pharmaceutically acceptable salt thereof in amount of about 80% or more, preferably about 85% in the weight of the active ingredient based on the total weight of the composition.
IN5549CH2012 2012-12-31 2013-12-27 IN2012CH05549A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/IB2013/061370 WO2014102745A1 (en) 2012-12-31 2013-12-27 High drug load ibuprofen sustained release composition
IN5549CH2012 IN2012CH05549A (en) 2012-12-31 2013-12-27

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN5549CH2012 IN2012CH05549A (en) 2012-12-31 2013-12-27

Publications (1)

Publication Number Publication Date
IN2012CH05549A true IN2012CH05549A (en) 2015-07-03

Family

ID=51019974

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5549CH2012 IN2012CH05549A (en) 2012-12-31 2013-12-27

Country Status (2)

Country Link
IN (1) IN2012CH05549A (en)
WO (1) WO2014102745A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201502077D0 (en) * 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd Improved hme technology
US11510877B2 (en) 2017-10-10 2022-11-29 Capsugel Belgium Nv Gelling multiparticulates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form

Also Published As

Publication number Publication date
WO2014102745A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
WO2015120110A3 (en) Novel pharmaceutical formulations
WO2015018380A3 (en) Therapeutic nanoparticles and the preparation methods thereof
EP3626253A3 (en) Stable formulations of linaclotide
MX2013014788A (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]am ino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids.
MX2011007817A (en) Controlled release pharmaceutical or food formulation and process for its preparation.
GB2495676A (en) Use of binders for manufacturing storage stable formulations
PH12015501096A1 (en) Composition for immediate and extended release
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
PH12014502512A1 (en) Topical pharmaceutical compositions comprising terbinafine and urea
TN2015000135A1 (en) Modified release formulations for oprozomib
MX344846B (en) Combination of active loaded granules with additional actives.
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
PH12016500865A1 (en) Composite formulation comprising tadalafil and amlodipine
WO2014056824A3 (en) Oral care composition
WO2012085284A3 (en) High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
WO2012085249A3 (en) Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid
WO2014006636A3 (en) Stable compositions of fesoterodine
EP2871187A4 (en) Novel compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient
IN2012CH05549A (en)
MX357704B (en) O/w-emulsion-type topical pharmaceutical compositions containing a retinoid.
SI2722322T1 (en) 1,3-di-oxo-indene derivative, pharmaceutically acceptable salt or optical isomer thereof, preparation method thereof, and pharmaceutical composition containing same as an antiviral, active ingredient
WO2013072770A3 (en) Pharmaceutical formulations comprising atorvastatin and glimepiride
EP2842938A4 (en) Novel beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient
WO2011161223A3 (en) Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts